Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

185.28 -22.34 (-10.76%)
Streaming Delayed Price Updated: 12:06 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 604,014
Open 195.52
Bid (Size) 184.76 (1)
Ask (Size) 185.35 (2)
Prev. Close 207.62
Today's Range 184.74 - 196.96
52wk Range 126.97 - 248.16
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
From BeiGene, Ltd.
Via Business Wire
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
+4.68%
+4.68%
1 Month
-9.64%
-9.64%
3 Month
-4.15%
-4.15%
6 Month
+18.72%
+18.72%
1 Year
+6.15%
+6.15%

More News

Read More
A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts
Via Benzinga
Why Is BeiGene Stock Trading Higher On Wednesday?
Via Benzinga
Expert Outlook: BeiGene Through The Eyes Of 4 Analysts
Via Benzinga
What Analysts Are Saying About BeiGene Stock
Via Benzinga
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
From BeiGene, Ltd.
Via Business Wire
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
From BeiGene, Ltd.
Via Business Wire
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Mourns Death of Beloved Board Member Donald Glazer
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
From BeiGene, Ltd.
Via Business Wire
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
From BeiGene, Ltd.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.